Akston Biosciences, a developer of new classes of biologic therapeutics, and Biolexis, a division of Stelis Biopharma, have entered into a licensing, manufacturing and commercialization agreement for Akston’s AKS-452, a protein subunit COVID-19 vaccine. Under the agreement, Biolexis gains the right to manufacture and commercialize AKS-452 (branded as AmbiVax-C) in India and over 130 countries in Asia, Latin America and Africa largely covering the low-and-middle-income countries (LMICs). Biolexis...